{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27256556",
  "DateCompleted": {
    "Year": "2017",
    "Month": "05",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "06",
        "Day": "03"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/nrn.2016.57"
    ],
    "Journal": {
      "ISSN": "1471-0048",
      "JournalIssue": {
        "Volume": "17",
        "Issue": "8",
        "PubDate": {
          "Year": "2016",
          "Month": "Aug"
        }
      },
      "Title": "Nature reviews. Neuroscience",
      "ISOAbbreviation": "Nat Rev Neurosci"
    },
    "ArticleTitle": "Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.",
    "Pagination": {
      "StartPage": "524",
      "EndPage": "532",
      "MedlinePgn": "524-32"
    },
    "Abstract": {
      "AbstractText": [
        "The dopamine system is unique among the brain's modulatory systems in that it has discrete projections to specific brain regions involved in motor behaviour, cognition and emotion. Dopamine neurons exhibit several activity patterns - including tonic and phasic firing - that are determined by a combination of endogenous pacemaker conductances and regulation by multiple afferent systems. Emerging evidence suggests that disruptions in these regulatory systems may underlie the pathophysiology of several psychiatric disorders, including schizophrenia and depression."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departments of Neuroscience, Psychiatry and Psychology, Department of Neuroscience, A210 Langley Hall, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA."
          }
        ],
        "LastName": "Grace",
        "ForeName": "Anthony A",
        "Initials": "AA"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 MH057440",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH101180",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R21 MH104320",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nat Rev Neurosci",
    "NlmUniqueID": "100962781",
    "ISSNLinking": "1471-003X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "VTD58H1Z2X",
      "NameOfSubstance": "Dopamine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Brain"
    },
    {
      "QualifierName": [
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Dopamine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Neurons"
    },
    {
      "QualifierName": [
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Schizophrenia"
    }
  ],
  "CoiStatement": "The author has received honoraria/research support from the following organizations: Johnson & Johnson, Lundbeck, Pfizer, GSK, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, Asubio, Abbott, Autofony, Janssen"
}